JP7813730B2 - 甲状腺様作用剤 - Google Patents

甲状腺様作用剤

Info

Publication number
JP7813730B2
JP7813730B2 JP2022577454A JP2022577454A JP7813730B2 JP 7813730 B2 JP7813730 B2 JP 7813730B2 JP 2022577454 A JP2022577454 A JP 2022577454A JP 2022577454 A JP2022577454 A JP 2022577454A JP 7813730 B2 JP7813730 B2 JP 7813730B2
Authority
JP
Japan
Prior art keywords
formula
compound
pharmaceutically acceptable
disease
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022577454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530709A (ja
JP2023530709A5 (enExample
Inventor
ゲルデルン，トーマス フォン
バックス，ブラッドリー
Original Assignee
オートバーン セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オートバーン セラピューティクス，インク． filed Critical オートバーン セラピューティクス，インク．
Publication of JP2023530709A publication Critical patent/JP2023530709A/ja
Publication of JP2023530709A5 publication Critical patent/JP2023530709A5/ja
Application granted granted Critical
Publication of JP7813730B2 publication Critical patent/JP7813730B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/367—Halogenated derivatives polycyclic non-condensed, containing only six-membered aromatic rings as cyclic parts, e.g. halogenated poly-hydroxyphenylalkanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022577454A 2020-06-17 2021-06-17 甲状腺様作用剤 Active JP7813730B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063040446P 2020-06-17 2020-06-17
US63/040,446 2020-06-17
PCT/US2021/037788 WO2021257804A1 (en) 2020-06-17 2021-06-17 Thyromimetics

Publications (3)

Publication Number Publication Date
JP2023530709A JP2023530709A (ja) 2023-07-19
JP2023530709A5 JP2023530709A5 (enExample) 2024-06-20
JP7813730B2 true JP7813730B2 (ja) 2026-02-13

Family

ID=79268411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022577454A Active JP7813730B2 (ja) 2020-06-17 2021-06-17 甲状腺様作用剤

Country Status (5)

Country Link
US (1) US12590072B2 (enExample)
EP (1) EP4167986A4 (enExample)
JP (1) JP7813730B2 (enExample)
CN (1) CN115916214B (enExample)
WO (1) WO2021257804A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022008626A (es) * 2020-01-13 2022-08-22 Eccogene Shanghai Co Ltd Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
WO2022184177A1 (zh) * 2021-03-04 2022-09-09 甫康（上海）健康科技有限责任公司 一种芳香化合物、其制备方法及其应用
CN117362149A (zh) * 2023-12-08 2024-01-09 山东华安新材料有限公司 一种2,4,6-三氟溴苄的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001114768A (ja) 1999-09-30 2001-04-24 Pfizer Prod Inc 甲状腺受容体リガンドとしての６−アザウラシル誘導体
JP2001226359A (ja) 2000-01-25 2001-08-21 Pfizer Prod Inc 甲状腺受容体リガンドとしてのテトラゾール化合物
JP2002053564A (ja) 2000-04-21 2002-02-19 Pfizer Prod Inc 甲状腺受容体リガンド
WO2007132475A1 (en) 2006-05-15 2007-11-22 Cadila Healthcare Limited Selective tr-beta 1 agonist
JP2019524814A (ja) 2016-08-12 2019-09-05 オレゴン ヘルス アンド サイエンス ユニバーシティ アミド化合物、その医薬組成物、及びその使用方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4723027A (en) 1982-11-22 1988-02-02 E. I. Du Pont De Nemours And Company Preparation of optically active alpha-hydroxynitriles
ZA837994B (en) 1982-11-22 1984-06-27 Shell Oil Co Process for the preparation of optically-active cyanomethyl esters
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4741897A (en) 1986-07-08 1988-05-03 Baxter Travenol Thyroxine analogs and reagents for thyroid hormone assays
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
DE69333894D1 (de) 1992-04-22 2005-12-01 Ligand Pharm Inc Verbindungen mit Retinoid x rezeptorselektivität
DE4320444A1 (de) 1993-06-21 1994-12-22 Agfa Gevaert Ag Farbfotografisches Aufzeichnungsmaterial
JP2000502086A (ja) 1995-12-13 2000-02-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 核レセプターのリガンドおよびリガンド結合ドメイン
JPH09301917A (ja) 1996-05-08 1997-11-25 Koichi Shudo 甲状腺ホルモン作用性化合物
CA2260992C (en) 1996-08-20 2004-03-09 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
JP2002519340A (ja) 1998-06-30 2002-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 甲状腺ホルモン類似体およびそれらの調製方法
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
EP1194422A1 (en) 1999-06-01 2002-04-10 University Of Texas Southwestern Medical Center Biaryl compounds
US6787652B1 (en) 1999-09-30 2004-09-07 Pfizer, Inc. 6-Azauracil derivatives as thyroid receptor ligands
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
PL201790B1 (pl) 2000-02-17 2009-05-29 Bristol Myers Squibb Co Anilinopochodny ligand dla receptora tarczycy, jego zastosowanie i kompozycja farmaceutyczna
DE10024939A1 (de) 2000-05-19 2001-11-29 Bayer Ag Neue Diphenylmethanderivate für Arzneimittel
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
US20040267015A1 (en) 2001-04-05 2004-12-30 Ajita Bhat Peptide deformylase inhibitors
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
EP1497270A4 (en) 2002-03-27 2006-01-04 Smithkline Beecham Corp AMID COMPOUNDS AND METHOD FOR THEIR USE
US7302347B2 (en) 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
US7321065B2 (en) 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US8071134B2 (en) 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2006012015A2 (en) 2004-06-29 2006-02-02 Oregon Health And Science University Methods and compositions for nerve regeneration
CA2583410A1 (en) 2004-09-15 2006-03-23 Albany College Of Pharmacy Thyroid hormone analogs for promoting angiogenesis
MX2007010076A (es) 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
RU2007148927A (ru) 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
CN101180097A (zh) 2005-05-26 2008-05-14 症变治疗公司 新型含次膦酸的拟甲状腺素药
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
AU2006249347A1 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
DE102005056930A1 (de) * 2005-11-29 2007-05-31 Infineon Technologies Ag Halbleiter-Bauelement-Test-Verfahren, Halbleiter-Bauelement-Testgerät, sowie zwischen ein Testgerät und ein zu testendes Halbleiter-Bauelement geschaltete Einrichtung
GB0606212D0 (en) 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
GB0608724D0 (en) 2006-05-03 2006-06-14 Karobio Ab Novel Pharmaceutical Compositions
NZ576424A (en) 2006-10-20 2012-09-28 Biogen Idec Inc Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8623861B2 (en) 2006-11-03 2014-01-07 Xin-Min Li Method of treating demyelination diseases
EP2656879B1 (en) 2006-12-10 2017-06-28 Chongxi Yu Transdermal delivery systems of beta-lactam antibiotics
AU2008226541B2 (en) 2007-03-09 2013-05-09 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
FI20075245A0 (fi) 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
CA2693697C (en) 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
WO2009097995A1 (de) 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
EP2136317B1 (en) * 2008-06-19 2013-09-04 Samsung Electronics Co., Ltd. Method and apparatus for recognizing characters
US8475804B2 (en) 2009-02-20 2013-07-02 U.S. Army Medical Research And Material Command Compositions and methods for treatment of filovirus-mediated diseases
WO2010148007A2 (en) 2009-06-17 2010-12-23 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
WO2011041686A1 (en) 2009-10-01 2011-04-07 Mount Sinai School Of Medicine Of New York University Human type 1 taste receptor subunit 3 modulators and methods of using same
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
US20140288077A1 (en) 2011-07-05 2014-09-25 St. Jude Children's Research Hospital Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
WO2013056232A2 (en) 2011-10-13 2013-04-18 Case Western Reserve University Rxr agonists compounds and methods
WO2014078892A1 (en) 2012-11-21 2014-05-30 Indyk Daniel A device and a test assembly for testing the integrity of a low voltage electrical network
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
MX2016000724A (es) 2013-07-22 2016-04-13 Metabolic Solutions Dev Co Llc Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas.
US10258613B2 (en) 2014-02-05 2019-04-16 The Board Of Regents Of The University Of Oklahoma Compositions for treating retinal degeneration and methods of production and use thereof
EP3152190B1 (en) 2014-06-04 2024-07-31 Haro Pharmaceutical Inc. 18-20 member bi-polycyclic compounds
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
PE20180021A1 (es) 2015-02-20 2018-01-09 Univ Oregon Health & Science Derivados de sobetiroma
WO2017015360A1 (en) 2015-07-20 2017-01-26 Oregon Health & Science University Quinolone-3-diarylethers
US11872207B2 (en) 2015-12-24 2024-01-16 Mcmaster University Dronedarone and derivatives thereof for treating cancer
MX382313B (es) 2016-05-18 2025-03-13 Univ Oregon Health & Science Derivados del sobetiroma.
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
MX2020008498A (es) 2018-02-14 2020-09-25 Univ Oregon Health & Science Derivados de sobetirome.
CN111801013B (zh) 2018-03-02 2021-12-24 俄勒冈健康科学大学 小分子核受体调节剂的酰胺前药
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EP3894383A1 (en) 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020118564A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
CN119431265A (zh) 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
CN115279359A (zh) 2019-11-29 2022-11-01 速通医疗公司 新型拟甲状腺素药
MX2022008626A (es) * 2020-01-13 2022-08-22 Eccogene Shanghai Co Ltd Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.
WO2021247847A1 (en) 2020-06-03 2021-12-09 Autobahn Therapeutics, Inc. Isotopic thyromimetic compounds
WO2021257834A1 (en) 2020-06-17 2021-12-23 Autobahn Therapeutics, Inc. Thyromimetics
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001114768A (ja) 1999-09-30 2001-04-24 Pfizer Prod Inc 甲状腺受容体リガンドとしての６−アザウラシル誘導体
JP2001226359A (ja) 2000-01-25 2001-08-21 Pfizer Prod Inc 甲状腺受容体リガンドとしてのテトラゾール化合物
JP2002053564A (ja) 2000-04-21 2002-02-19 Pfizer Prod Inc 甲状腺受容体リガンド
WO2007132475A1 (en) 2006-05-15 2007-11-22 Cadila Healthcare Limited Selective tr-beta 1 agonist
JP2019524814A (ja) 2016-08-12 2019-09-05 オレゴン ヘルス アンド サイエンス ユニバーシティ アミド化合物、その医薬組成物、及びその使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry，2005年，Vol.13，pp.3627-3639

Also Published As

Publication number Publication date
JP2023530709A (ja) 2023-07-19
CN115916214A (zh) 2023-04-04
US20230242492A1 (en) 2023-08-03
US12590072B2 (en) 2026-03-31
EP4167986A4 (en) 2024-11-20
CN115916214B (zh) 2026-03-03
WO2021257804A1 (en) 2021-12-23
EP4167986A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
US12466781B2 (en) Thyromimetics
US12590072B2 (en) Thyromimetics
JP7503560B2 (ja) 新規な甲状腺模倣物
US11827596B2 (en) Thyromimetics
US12528761B2 (en) Thyromimetics
JP6217866B2 (ja) Ｋｃｎｑ２〜５チャネル活性化剤
EP3609888A1 (en) Farnesoid x receptor agonists and uses thereof
WO2020118564A1 (en) Novel thyromimetics
WO2021257834A1 (en) Thyromimetics
JP7664278B2 (ja) ファルネソイドｘ受容体アゴニストの結晶質形態
JP6197971B1 (ja) Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
JP2020505413A (ja) Ｒｏｒガンマモジュレーター及びその使用
EA048616B1 (ru) Новые тиромиметики
JP2000191664A (ja) 縮合ピリダジン誘導体、その製造法および用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250423

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251021

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260202

R150 Certificate of patent or registration of utility model

Ref document number: 7813730

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150